PMGC Holdings Inc. reports news across a holding-company portfolio that includes precision manufacturing, aerospace and defense supply-chain operations, industrial packaging, defense technology, and bioscience subsidiaries. Recurring company updates cover subsidiary long-term supply agreements, ITAR and aerospace quality standards, customer relationships, manufacturing capacity, and capital actions tied to acquisition-led platform development.
PMGC news also covers NorthStrive Biosciences patent filings and manufacturing work for engineered probiotic assets such as EL-22 and EL-32, as well as Pacific Sun Packaging activity in electronics and IT hardware packaging markets. Defense technology announcements describe subsidiary initiatives involving autonomous systems, counter-drone applications, and GPS-denied navigation environments.
PMGC Holdings (NASDAQ: ELAB) has completed a common-share investment in Australian space technology company Orbit2Orbit through its investment arm, PMGC Capital.
The subscription was part of Orbit2Orbit’s private placement financing connected with its proposed Canadian Securities Exchange listing through a reverse takeover transaction. Orbit2Orbit develops in-space logistics and infrastructure. The investment expands PMGC’s exposure to the commercial space economy alongside its U.S. precision manufacturing platform, which serves aerospace, defense and space customers.
PMGC believes space-sector growth is increasing demand for U.S.-based manufacturing and engineering of spacecraft components and flight hardware. The company plans to continue building these capabilities across its manufacturing sites.
PMGC Holdings (Nasdaq: ELAB) completed a preclinical study of subsidiary NorthStrive Biosciences’ EL-32, finding dose-specific signals when combined with semaglutide.
The eight-week study in obese mice found statistically greater absolute lean mass at the highest combination dose versus semaglutide alone, but no significant relative lean-mass difference. The lowest combination dose improved relative glucose response during insulin tolerance testing. Added weight reduction was statistically significant at the high dose on the final treatment day, but not consistently throughout treatment.
The combination showed no consistent additive metabolic benefit over semaglutide alone, and EL-32 alone showed little benefit. NorthStrive plans another preclinical study using lower-dose semaglutide, considering lean mass and body composition as primary endpoints, with a design and timing update expected in Q1 2027. The findings do not establish human efficacy.
NorthStrive Acquisition Corp I (Nasdaq: NSAI) signed a business combination agreement valuing nuclear technology developer Nuclea Energy at $350 million. That enterprise value is subject to closing adjustments. The transaction is expected to close in the first half of 2027, with NorthStrive expected to become Nuclea-X and list on Nasdaq. Nuclea shareholders would receive Class A shares valued at $10.00 per share, plus conditional earnout shares.
Closing requires shareholder approvals, an effective registration statement, Nasdaq listing approval, a minimum cash condition and completion of Nuclea's pending Moltex acquisition, including required governmental clearances. Dissent rights must not be exercised over more than 5% of Nuclea shares. Both boards unanimously approved the deal; holders of at least 66 2/3% of Nuclea shares signed voting agreements. Nuclea's current management is expected to lead the combined company.
PMGC Holdings (Nasdaq: ELAB) has registered NorthStrive Holdings as its doing-business-as name and signed a trademark license agreement with NorthStrive Companies. The company will use the new name immediately for acquisition and operating activities, special purpose acquisition companies, and corporate communications. The agreement authorizes use of the NorthStrive® name, logo and associated marks.
The company intends to complete a formal legal name change within approximately six months, subject to applicable SEC, Nasdaq, state and regulatory filings. Its ticker and existing filings remain unchanged for now. The corporate website has been updated to reflect the licensed branding.
PMGC Holdings (Nasdaq: ELAB) launched its SPAC sponsorship platform with NorthStrive Acquisition Corp. I completing a $100 million initial public offering. NorthStrive issued 10,000,000 units. PMGC's sponsor position is approximately 2.7 million shares, or roughly 21.4% of NorthStrive's Class A shares on an as-converted basis.
A SPAC is a company formed to combine with another business. NorthStrive has not selected a target and intends to focus on manufacturers serving aerospace and defense, industrial technology, and critical supply chains. PMGC has also incorporated NorthStrive Acquisition Corp. II. PMGC intends the platform to complement direct acquisitions by providing economic participation in larger or differently structured transactions through sponsor and founder shares. It expects to maintain a majority economic interest in the applicable sponsor and its founder shares.
PMGC Holdings (ELAB) subsidiary NorthStrive Biosciences signed a statement of work with Charles River Laboratories for testing of EL-22 and EL-32.
Charles River will measure plasmid copy numbers in the engineered probiotic candidates at its U.S. Biologics Testing sites. The work includes DNA isolation and preparation, followed by gene copy-number analysis. NorthStrive intends to use the resulting data to support product identity, manufacturing consistency and comparisons with previously manufactured material as the programs move toward an IND-enabling development framework.
PMGC Holdings (ELAB) executed an interest-bearing payment agreement with Longevity Health Holdings converting Elevai Skincare royalty obligations into scheduled cash payments through August 28, 2031.
The plan covers Longevity’s acknowledged 2025 royalty of $94,937, accruing interest at the Wall Street Journal Prime Rate plus 1.00% per annum from its original April 2026 due date. PMGC’s subsidiary NorthStrive Biosciences will receive $10,000 monthly starting October 15, 2026, with all amounts due by August 2031. All future royalties and earnouts from the Elevai Skincare sale automatically roll into the same interest-bearing plan, which includes 15% mandatory prepayments from specified capital events and is described as creating recurring, non-dilutive cash flow for PMGC.
PMGC Holdings (NASDAQ: ELAB), via subsidiary NorthStrive Biosciences, executed a First Amendment to its Development and License Agreement with Yuva Biosciences, launching a structured three-phase, six-month Expansion Program to advance four AI-discovered small-molecule compounds toward lead and backup nomination for potential Cardiac Disease and Obesity applications.
The program builds on positive Phase III results in which all four candidates, identified by Yuva’s MitoNova AI platform, showed statistically significant ANT1 protein increases in primary human skeletal muscle cells. The Amendment also clarifies and strengthens NorthStrive’s exclusive Cardiac Disease and Obesity field of use and grants a right of first refusal to negotiate an exclusive license across the broader cardiometabolic field during the agreement term and for one year after Expansion Phase III completion.
PMGC Holdings (Nasdaq: ELAB) announced it has terminated a previously disclosed non-binding LOI to acquire a 76% controlling interest in an Arizona-based precision machining and contract manufacturing company, after completing audit-stage financial due diligence and determining the total transaction cost no longer met its risk-adjusted return criteria.
The target had earlier provided unaudited fiscal 2025 figures of approximately $5.46 million revenue and $1.05 million EBITDA, which were subject to audit. PMGC reported that the diligence showed a less favorable historical financial profile than management anticipated and chose not to proceed. The company incurred no breakup fee or termination penalty.
PMGC highlighted an active M&A pipeline, with its dedicated team evaluating multiple bolt-on, standalone and carve-out opportunities under a disciplined valuation and returns framework. Concurrently, PMGC is increasing investment in its aerospace and defense manufacturing portfolio, adding advanced machining equipment such as a 5-axis machining center, CNC lathes and a Swiss-type CNC lathe that supports lights-out manufacturing and greater automation. PMGC is also assessing additional robotics, automation and production monitoring technologies to extend operating hours and increase output. In 2026 it merged two precision manufacturing businesses to consolidate functions, share resources and improve equipment utilization, and plans to evaluate similar integration opportunities across its broader portfolio.
PMGC Holdings (Nasdaq: ELAB) entered into a non-binding term sheet with space technology company Orbit2Orbit outlining a proposed three-part strategic relationship. The contemplated transactions include a Mice2Space microgravity research collaboration using NorthStrive Biosciences’ myostatin and activin A candidates EL-22 and EL-32, a U.S. aerospace manufacturing partnership, and a strategic equity investment.
Under the term sheet, NorthStrive Bio would study EL-22 and EL-32 in mice on Orbit2Orbit’s platform, with Orbit2Orbit leading payload engineering in Australia and PMGC subsidiary A&B Aerospace manufacturing final flight hardware in the U.S. PMGC also intends to invest CAD $200,000 in Orbit2Orbit at CAD $0.80 per share, tied to Orbit2Orbit’s private placement and planned Canadian Securities Exchange listing via reverse takeover. All transactions are subject to due diligence, definitive agreements, approvals, and may not be completed.